This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Nedocromil sodium

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Nedocromil sodium is indicated for the prophylaxis of asthma.

It may be used in conjunction with inhaled beta-2 agonists and corticosteroids to allow the reduction in the dose of either or both drugs.

Withdrawal of sodium cromoglicate inhaler in the UK (1):

  • the asthma preventer inhaler Intal (sodium cromoglicate) is being discontinued, with stock expected to be exhausted by the end of January 2022
  • the BTS/SIGN asthma guideline considers inhaled corticosteroids to be the first-choice preventer drug, and sodium cromoglicate as an alternative but less effective preventer therapy
  • the Global Initiative for Asthma (GINA) does not recommend the use of chromones in children age 6-11 years because of low efficacy, and does not include this class of agent as a treatment option in adults

Reference:

  • NHS. Medicine Supply Notification(8/11/2021) - Sodium cromoglicate (Intal (R)) CFC-free 5mg inhaler

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.